Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Trevi Therapeutics, Inc.TRVI · Entity 4387 | Director | June 03, 2026 | June 04, 2026 |
| Vericel CorpVCEL · Entity 4481 | Director · President and CEO | February 24, 2026 | February 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Trevi Therapeutics, Inc.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Nonstatutory Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.45 · Expires 2036-06-02 | Direct | 35,000 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 35,000 · Balance 35,000 F1: This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer.
Vericel Corp
Report date February 24, 2026 · Filed February 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 303,020 |
Reported balance
After 2026-02-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-24 · Exercise / conversion · Acquired 18,250 · Balance 303,020 F1: The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date. F2: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 18,250 shares of Common Stock and instead received 18,250 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F3: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| Common StockSEC Table I · non-derivative | Direct | 321,270 |
Reported balance
After 2026-02-24 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-02-24 · Exercise / conversion · Acquired 18,250 · Balance 321,270 F4: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. F3: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| Common StockSEC Table I · non-derivative | Direct | 312,446 |
Reported balance
After 2026-02-24 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-02-24 · Tax withholding · Disposed 8,824 · Balance 312,446 F5: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F3: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 36,500 |
Reported balance
After 2026-02-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-24 · Exercise / conversion · Acquired 18,250 · Balance 36,500 F6: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F2: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 18,250 shares of Common Stock and instead received 18,250 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F7: No expiration date for this type of award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 54,750 |
Reported balance
After 2026-02-24 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-24 · Exercise / conversion · Acquired 18,250 · Balance 54,750 F6: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F8: The Fair Market Value of the vested derivative securities is $38.09 per share. F4: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. F7: No expiration date for this type of award. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date.
F2: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 18,250 shares of Common Stock and instead received 18,250 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.
F3: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F4: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively.
F5: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs.
F6: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
F7: No expiration date for this type of award.
F8: The Fair Market Value of the vested derivative securities is $38.09 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2023 Filed Feb 23, 2023 01:48 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 11,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-006577 · form4.xml · derivative · entry 8 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,100 Underlying: Common Stock · 11,700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F9 · price: The Fair Market Value of the vested derivative securities is $29.82 per share. F3 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 18, 2022. The remaining RSUs will vest in annual installments on February 18, 2024, February 18, 2025, and February 18, 2026, respectively. F8 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 18, 2023 Filed Feb 23, 2023 01:48 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 11,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006577 · form4.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 18, 2022. The remaining RSUs will vest in annual installments on February 18, 2024, February 18, 2025, and February 18, 2026, respectively. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 18, 2023 Filed Feb 23, 2023 01:48 UTC | Vericel Corp VCEL · Entity 4481 | Tax withholdingCommon Stock | 5,423 | $29.82 | $161,713.86 |
DisclosureSEC source: 0001127602-23-006577 · form4.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,013 F1 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 01:48 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 73,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006577 · form4.xml · derivative · entry 7 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,000 Underlying: Common Stock · 73,000 shares Expires not disclosed F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F7 · derivative.exercise_date: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 17, 2024. The remaining RSUs will vest in annual installments on February 17, 2025, February 17, 2026, and February 17, 2027, respectively. F8 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 01:48 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (Right to Buy) · Derivative | 179,147 | $0.00 Strike: $29.82 | $0.00 |
DisclosureSEC source: 0001127602-23-006577 · form4.xml · derivative · entry 6 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,147 Underlying: Common Stock · 179,147 shares Expires 2033-02-17 F5 · derivative.exercise_date: These options shall begin vesting on February 17, 2023 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 01:48 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (Right to Buy) · Derivative | 3,353 | $0.00 Strike: $29.82 | $0.00 |
DisclosureSEC source: 0001127602-23-006577 · form4.xml · derivative · entry 5 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,353 Underlying: Common Stock · 3,353 shares Expires 2033-02-17 F5 · derivative.exercise_date: These options shall begin vesting on February 17, 2023 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 21:04 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-005115 · form4.xml · derivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · price: The Fair Market Value of the vested derivative securities is $29.30 per share. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest on February 11, 2024. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 21:04 UTC | Vericel Corp VCEL · Entity 4481 | Tax withholdingCommon Stock | 3,515 | $29.30 | $102,989.50 |
DisclosureSEC source: 0001127602-23-005115 · form4.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,736 F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 21:04 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005115 · form4.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest on February 11, 2024. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:01 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 6,938 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-003985 · form4.xml · derivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,938 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · price: The Fair Market Value of the vested derivative securities is $30.60 per share. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 6, 2019. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:01 UTC | Vericel Corp VCEL · Entity 4481 | Tax withholdingCommon Stock | 3,253 | $30.60 | $99,541.80 |
DisclosureSEC source: 0001127602-23-003985 · form4.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,751 F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:01 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 6,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-003985 · form4.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 6, 2019. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 21:11 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 39,938 | $0.00 Strike: $25.80 | $0.00 |
DisclosureSEC source: 0001127602-23-001340 · form4.xml · derivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,938 shares Expires 2023-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 55,001 shares, became exercisable on March 6, 2014, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal monthly installments over three years thereafter, contingent upon continued service to the Company. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 21:11 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 39,938 | $27.13 | $1,083,597.82 |
DisclosureSEC source: 0001127602-23-001340 · form4.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,066 F2 · shares: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 21:11 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 39,938 | $25.80 | $1,030,400.40 |
DisclosureSEC source: 0001127602-23-001340 · form4.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 23, 2022 Filed Jun 23, 2022 20:41 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantNonstatutory Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001209191-22-038906 · doc4.xml · derivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-22 F1 · derivative.exercise_date: This option was granted on June 23, 2022. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer. Read SEC document |
| June 23, 2022 Filed Jul 1, 2022 20:54 UTC Amendment | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantNonstatutory Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001209191-22-040294 · doc4a.xml · derivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-22 F1 · derivative.exercise_date: This option was granted on June 23, 2022. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer. F2 · ownership.direct: This amendment to the Form 4 originally filed for the reporting person on June 23, 2022 is being filed solely to attach the power of attorney exhibit that was inadvertently excluded from the original filing. Read SEC document |
| February 19, 2022 Filed Feb 22, 2022 21:07 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 8,937 | $34.90 | $311,901.30 |
DisclosureSEC source: 0001593968-22-000514 · primary_01.xml · derivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,813 Underlying: Common Stock · 8,937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest in annual installments on February 19, 2023, February 19, 2024, and February 19, 2025, respectively. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 19, 2022 Filed Feb 22, 2022 21:07 UTC | Vericel Corp VCEL · Entity 4481 | Tax withholdingCommon Stock | 3,875 | $34.90 | $135,237.50 |
DisclosureSEC source: 0001593968-22-000514 · primary_01.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,432 F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 19, 2022 Filed Feb 22, 2022 21:07 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 8,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-000514 · primary_01.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest in annual installments on February 19, 2023, February 19, 2024, and February 19, 2025, respectively. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:07 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 46,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-000514 · primary_01.xml · derivative · entry 6 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,800 Underlying: Common Stock · 46,800 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F7 · derivative.exercise_date: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 18, 2023. The remaining RSUs will vest in annual installments on February 18, 2024, February 18, 2025, and February 18, 2026, respectively. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:07 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 270,135 | $0.00 Strike: $34.90 | $0.00 |
DisclosureSEC source: 0001593968-22-000514 · primary_01.xml · derivative · entry 5 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,135 Underlying: Common Stock · 270,135 shares Expires 2032-02-18 F6 · derivative.exercise_date: These options shall begin vesting on February 18, 2022 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:07 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 2,865 | $0.00 Strike: $34.90 | $0.00 |
DisclosureSEC source: 0001593968-22-000514 · primary_01.xml · derivative · entry 4 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,865 Underlying: Common Stock · 2,865 shares Expires 2032-02-18 F6 · derivative.exercise_date: These options shall begin vesting on February 18, 2022 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:48 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 7,500 | $35.26 | $264,450.00 |
DisclosureSEC source: 0001593968-22-000468 · primary_01.xml · derivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest in annual installments on February 11, 2023, and February 11, 2024, respectively. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:48 UTC | Vericel Corp VCEL · Entity 4481 | Tax withholdingCommon Stock | 3,251 | $35.26 | $114,630.26 |
DisclosureSEC source: 0001593968-22-000468 · primary_01.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,370 F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:48 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-000468 · primary_01.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest in annual installments on February 11, 2023, and February 11, 2024, respectively. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 06, 2022 Filed Feb 8, 2022 22:01 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 6,937 | $33.91 | $235,233.67 |
DisclosureSEC source: 0001593968-22-000421 · primary_01.xml · derivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,938 Underlying: Common Stock · 6,937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting person as a result of the vesting of RSUs granted to the Reporting Person on February 6, 2019. The remaining RSUs will vest on February 6, 2023. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 06, 2022 Filed Feb 8, 2022 22:01 UTC | Vericel Corp VCEL · Entity 4481 | Tax withholdingCommon Stock | 3,049 | $33.91 | $103,391.59 |
DisclosureSEC source: 0001593968-22-000421 · primary_01.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,121 F2 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of Restricted Stock Units. Read SEC document |
| February 06, 2022 Filed Feb 8, 2022 22:01 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 6,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-000421 · primary_01.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,170 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting person as a result of the vesting of RSUs granted to the Reporting Person on February 6, 2019. The remaining RSUs will vest on February 6, 2023. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 20:00 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantNonstatutory Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001209191-21-041389 · doc4.xml · derivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: This option was granted on June 16, 2021. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 20:15 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 7,563 | $0.00 Strike: $25.80 | $0.00 |
DisclosureSEC source: 0001593968-21-001129 · primary_01.xml · derivative · entry 5 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,938 Underlying: Common Stock · 7,563 shares Expires 2023-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These options, representing the right to purchase 55,001 shares, became exercisable on March 6, 2014, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal monthly installments over three years thereafter, contingent upon continued service to the Company. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 20:15 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 16,250 | $57.46 | $933,725.00 |
DisclosureSEC source: 0001593968-21-001129 · primary_01.xml · nonDerivative · entry 4 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,973 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 20:15 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 14,760 | $57.92 | $854,899.20 |
DisclosureSEC source: 0001593968-21-001129 · primary_01.xml · nonDerivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,223 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 20:15 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 7,563 | $25.80 | $195,125.40 |
DisclosureSEC source: 0001593968-21-001129 · primary_01.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,983 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: The Reporting Person has elected to exercise and hold these shares at this time. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 20:15 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 8,990 | $59.13 | $531,578.70 |
DisclosureSEC source: 0001593968-21-001129 · primary_01.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,420 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 30, 2021 Filed Mar 30, 2021 20:50 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $25.80 | $0.00 |
DisclosureSEC source: 0001593968-21-001029 · primary_01.xml · derivative · entry 6 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,501 Underlying: Common Stock · 7,500 shares Expires 2023-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 55,001 shares, became exercisable on March 6, 2014, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal monthly installments over three years thereafter, contingent upon continued service to the Company. Read SEC document |
| March 30, 2021 Filed Mar 30, 2021 20:50 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 7,500 | $25.80 | $193,500.00 |
DisclosureSEC source: 0001593968-21-001029 · primary_01.xml · nonDerivative · entry 5 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The Reporting Person has elected to exercise and hold these shares at this time. Read SEC document |
| March 29, 2021 Filed Mar 30, 2021 20:50 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 13,125 | $50.94 | $668,587.50 |
DisclosureSEC source: 0001593968-21-001029 · primary_01.xml · nonDerivative · entry 4 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,550 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| March 29, 2021 Filed Mar 30, 2021 20:50 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 10,313 | $50.93 | $525,241.09 |
DisclosureSEC source: 0001593968-21-001029 · primary_01.xml · nonDerivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,675 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| March 29, 2021 Filed Mar 30, 2021 20:50 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 15,552 | $51.09 | $794,551.68 |
DisclosureSEC source: 0001593968-21-001029 · primary_01.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,988 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| March 29, 2021 Filed Mar 30, 2021 20:50 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 1,010 | $51.36 | $51,873.60 |
DisclosureSEC source: 0001593968-21-001029 · primary_01.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,540 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:15 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 15,925 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001593968-21-000706 · primary_01.xml · derivative · entry 10 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,700 Underlying: Common Stock · 15,925 shares Expires 2027-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These options, representing the right to purchase a total of 210,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 8, 2017, which was one quarter after the date on which the option was granted. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:15 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 6,805 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001593968-21-000706 · primary_01.xml · derivative · entry 9 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,195 Underlying: Common Stock · 6,805 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase a total of 300,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 7, 2018, which was one quarter after the date on which the option was granted. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:15 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 5,625 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001593968-21-000706 · primary_01.xml · derivative · entry 8 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,125 Underlying: Common Stock · 5,625 shares Expires 2027-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 6.25% of these options, representing the right to purchase a total of 90,000 shares, became exercisable immediately on May 22, 2017. An additional 6.25% became exercisable on August 8, 2017 and continue to vest in equal quarterly installments from August 8, 2017, contingent upon the continued service to the Company. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:15 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 8,692 | $48.01 | $417,302.92 |
DisclosureSEC source: 0001593968-21-000706 · primary_01.xml · nonDerivative · entry 7 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,550 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:15 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 27,500 | $48.06 | $1,321,650.00 |
DisclosureSEC source: 0001593968-21-000706 · primary_01.xml · nonDerivative · entry 6 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,242 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:15 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 15,925 | $2.75 | $43,793.75 |
DisclosureSEC source: 0001593968-21-000706 · primary_01.xml · nonDerivative · entry 5 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,742 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:15 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 6,805 | $7.20 | $48,996.00 |
DisclosureSEC source: 0001593968-21-000706 · primary_01.xml · nonDerivative · entry 4 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:15 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 5,625 | $2.65 | $14,906.25 |
DisclosureSEC source: 0001593968-21-000706 · primary_01.xml · nonDerivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:15 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 2,260 | $48.78 | $110,242.80 |
DisclosureSEC source: 0001593968-21-000706 · primary_01.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,387 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.